No abstract available.
Hemorrhage* ; Pregnancy* ; Round Ligament of Uterus*

No abstract available.
Chlamydia* ; Fluorescent Antibody Technique, Indirect*

No abstract available.
Angiomyoma ; Ear

No abstract available
Apoptosis ; Humans* ; Thymocytes*

No abstract available.
Broad Ligament* ; Female ; Hemorrhage* ; Pregnancy*

Chronic pelvic pain is a common and significant disorder of women. It is estimated to have a prevalence of 3.8% in women. The etiology of chronic pelvic pain in women is poorly understood. Although a specific diagnosis is not found in the majority of cases, some common diagnoses include endometriosis, adhesions, irritable bowel syndrome, and interstitial cystitis. The initial history and physical examination can narrow the diagnostic possibilities, guide any subsequent evaluation, and rule out malignancy or significant systemic disease. If the initial evaluation does not reveal a specific diagnosis, a limited laboratory and ultrasound evaluation can clarify the diagnosis, as well as rule out serious disease and reassure the patient. Laboratory and imaging studies should be selectively utilized, as should laparoscopy. Conscious laparoscopic pain mapping has been proposed as a way to improve information derived from laparoscopic evaluations.
Cystitis, Interstitial ; Endometriosis ; Female ; Humans ; Irritable Bowel Syndrome ; Laparoscopy ; Pelvic Pain ; Physical Examination ; Prevalence

No abstract available.
Drug Therapy* ; Methotrexate* ; Uterine Cervical Neoplasms*

No abstract available.
Esophagus* ; Melanoma*

OBJECTIVE: To evaluate the effects of estrogen replacement therapy and pamidronate on the bone metabolism in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on biochemical markers of bone turnover in 140 women with low bone mass. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus alendronate (group III, n=40) for 12 months. Biochemical markers of bone turnover were also measured at months 6 and 12 months. RESULTS: Serum osteocalcin and urinary deoxypyridinoline in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.05). But total alkaline phosphatase decreased significantly during the treatment in Group III, but not in Group I and Group II. CONCLUSION: The combined treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing bone biochemical markers.
Alendronate ; Alkaline Phosphatase ; Biomarkers ; Estrogen Replacement Therapy* ; Estrogens* ; Female ; Humans ; Metabolism* ; Osteocalcin ; Osteoporosis ; Postmenopause ; Prospective Studies

No abstract available.
Female ; Laparoscopy* ; Methotrexate* ; Pregnancy ; Pregnancy, Ectopic*